Cytarabine - Latest Advances

Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia.

Journal: Cell cycle (Georgetown, Tex.)

Published: December 16, 2025

The promise of menin inhibitors: from approval to triplet regimens.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Effect and safety of a conditioning regimen with chidamide and BEAM for autologous hematopoietic stem cell transplantation in lymphoma

Journal: Zhonghua nei ke za zhi

Published: December 03, 2025

CHARACTERISTIC OF MYELOID SARCOMA BY CANCER GENOME PROFILING AND ALGORITHM OF POTENTIAL BIOMARKERS FOR UTERINE MESENCHYMAL TUMOR.

Journal: Georgian medical news

Published: November 28, 2025

Loss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms.

Journal: Experimental hematology

Published: November 25, 2025

Long-term follow-up of a case of Langerhans cell histiocytosis of the cervical spine with pulmonary involvement.

Journal: Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

Published: November 16, 2025

RETRACTED: Batool et al. Development and Evaluation of Cellulose Derivative and Pectin Based Swellable pH Responsive Hydrogel Network for Controlled Delivery of Cytarabine. Gels 2023, 9, 60.

Journal: Gels (Basel, Switzerland)

Published: November 12, 2025

CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia.

Journal: International journal of molecular sciences

Published: November 05, 2025

Treatment of high-risk acute myeloid leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: November 05, 2025

Acute myeloid leukemia therapy in the era of comprehensive genomic profiling

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: November 05, 2025

Comparative efficacy and safety of modified BEAM and BEAM/BEAC as conditioning regimens for autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.

Journal: Cell transplantation

Published: October 31, 2025

Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: October 31, 2025

Filters

Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia.

Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia.

The promise of menin inhibitors: from approval to triplet regimens.

The promise of menin inhibitors: from approval to triplet regimens.

Effect and safety of a conditioning regimen with chidamide and BEAM for autologous hematopoietic stem cell transplantation in lymphoma

Effect and safety of a conditioning regimen with chidamide and BEAM for autologous hematopoietic stem cell transplantation in lymphoma

CHARACTERISTIC OF MYELOID SARCOMA BY CANCER GENOME PROFILING AND ALGORITHM OF POTENTIAL BIOMARKERS FOR UTERINE MESENCHYMAL TUMOR.

CHARACTERISTIC OF MYELOID SARCOMA BY CANCER GENOME PROFILING AND ALGORITHM OF POTENTIAL BIOMARKERS FOR UTERINE MESENCHYMAL TUMOR.

Loss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms.

Loss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms.

Long-term follow-up of a case of Langerhans cell histiocytosis of the cervical spine with pulmonary involvement.

Long-term follow-up of a case of Langerhans cell histiocytosis of the cervical spine with pulmonary involvement.

RETRACTED: Batool et al. Development and Evaluation of Cellulose Derivative and Pectin Based Swellable pH Responsive Hydrogel Network for Controlled Delivery of Cytarabine. Gels 2023, 9, 60.

RETRACTED: Batool et al. Development and Evaluation of Cellulose Derivative and Pectin Based Swellable pH Responsive Hydrogel Network for Controlled Delivery of Cytarabine. Gels 2023, 9, 60.

CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia.

CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia.

Treatment of high-risk acute myeloid leukemia

Treatment of high-risk acute myeloid leukemia

Acute myeloid leukemia therapy in the era of comprehensive genomic profiling

Acute myeloid leukemia therapy in the era of comprehensive genomic profiling

Comparative efficacy and safety of modified BEAM and BEAM/BEAC as conditioning regimens for autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.

Comparative efficacy and safety of modified BEAM and BEAM/BEAC as conditioning regimens for autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.

Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.

Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.